-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, IYSndUyB2AixlxXhPT5wIEgxCIdhROMj+kqurOXNi0e1rKSQxRlEYYhMSOY4jQEX fY0FLeX12M24UaMIicpQJQ== 0001055947-04-000005.txt : 20040113 0001055947-04-000005.hdr.sgml : 20040113 20040113162524 ACCESSION NUMBER: 0001055947-04-000005 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20040109 FILED AS OF DATE: 20040113 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: BVF INC/IL CENTRAL INDEX KEY: 0001056807 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-31161 FILM NUMBER: 04522966 BUSINESS ADDRESS: STREET 1: 227 WEST MONROE STE STREET 2: STE 4800 CITY: CHICAGO STATE: IL ZIP: 60606 BUSINESS PHONE: 3122637777 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: ARENA PHARMACEUTICALS INC CENTRAL INDEX KEY: 0001080709 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 232908305 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 6166 NANCY RIDGE DR CITY: SAN DIEGO STATE: CA ZIP: 92121 BUSINESS PHONE: 8584537200 MAIL ADDRESS: STREET 1: 6166 NANCY RIDGE DR CITY: SAN DIEGO STATE: CA ZIP: 92121 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: BIOTECHNOLOGY VALUE FUND L P CENTRAL INDEX KEY: 0000918923 STANDARD INDUSTRIAL CLASSIFICATION: INVESTMENT ADVICE [6282] STATE OF INCORPORATION: DE FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-31161 FILM NUMBER: 04522969 BUSINESS ADDRESS: STREET 1: 227 W MONROE STREET, SUITE 4800 STREET 2: 227 W MONROE STREET, SUITE 4800 CITY: CHICAGO STATE: IL ZIP: 60606 BUSINESS PHONE: 415-288-23 MAIL ADDRESS: STREET 1: 227 W MONROE STREET, SUITE 4800 STREET 2: 227 W MONROE STREET, SUITE 4800 CITY: CHICAGO STATE: IL ZIP: 60606 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: BVF INVESTMENTS LLC CENTRAL INDEX KEY: 0001132245 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-31161 FILM NUMBER: 04522967 BUSINESS ADDRESS: STREET 1: ONE SANSOME ST. 39TH FL CITY: SAN FRANCISCO STATE: CA ZIP: 94104 BUSINESS PHONE: 3127392123 MAIL ADDRESS: STREET 1: C/O GROSVENOR CAPITAL MANAGEMENT LP STREET 2: 227 W. MONROE ST. #4800 CITY: CHICAGO STATE: IL ZIP: 60606 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: BVF PARTNERS L P/IL CENTRAL INDEX KEY: 0001055947 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-31161 FILM NUMBER: 04522970 BUSINESS ADDRESS: STREET 1: ONE SANSOME ST STREET 2: 39TH FL CITY: SAN FRANCISCO STATE: CA ZIP: 94104 BUSINESS PHONE: 3122637777 MAIL ADDRESS: STREET 1: 227 W MONROE STREET 2: SUITE 4800 CITY: CHICAGO STATE: IL ZIP: 60606 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: BIOTECHNOLOGY VALUE FUND II LP CENTRAL INDEX KEY: 0001102444 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-31161 FILM NUMBER: 04522968 BUSINESS ADDRESS: STREET 1: ONE SANSOME ST STREET 2: 39TH FL. CITY: SAN FRANCISCO STATE: CA ZIP: 94104 BUSINESS PHONE: 3122637777 MAIL ADDRESS: STREET 1: C/O GROSVENOR CAPITAL MANAGEMENT STREET 2: 227 W. MONROE ST #4800 CITY: CHICAGO STATE: IL ZIP: 60606 4 1 edgar.xml PRIMARY DOCUMENT X0201 42004-01-09 0001080709 ARENA PHARMACEUTICALS INC ARNA 0001055947 BVF PARTNERS L P/IL 227 West Monroe Street, Suite 4800ChicagoIL606060011Indirect Beneficial Owner 0000918923 BIOTECHNOLOGY VALUE FUND L P 227 West Monroe Street, Suite 4800ChicagoIL606060001 Direct Beneficial Owner 0001102444 BIOTECHNOLOGY VALUE FUND II LP 227 West Monroe Street, Suite 4800ChicagoIL606060001 Direct Beneficial Owner 0001132245 BVF INVESTMENTS LLC 227 West Monroe Street, Suite 4800ChicagoIL606060001 Direct Beneficial Owner 0001056807 BVF INC/IL ONE SANSOME STREET, 31ST FLOOR SAN FRANCISCO CA 94104 0011Indirect Beneficial OwnerCommon Stock2004-01-094S070006.30D995977ISee footnotes Common Stock2004-01-094S050006.30D640884ISee FootnotesCommon Stock2004-01-094S0120006.30D1672351ISee FootnotesThe shares reported in this response are beneficially owned by Biotechnology Value Fund, L.P., a Delaware limited partnership ("BVF, L.P.") (1,002,977 shares); Biotechnology Value Fund II, L.P., a Delaware limited partnership ("BVF2, L.P.") (645,884 shares); BVF Investments, L.L.C., a Delaware limited liability company ("Investments") (1,684,351 shares); and by BVF Partners L.P., a Delaware limited partnership ("Partners"), and by its general partner BVF Inc., a Delaware corporation ("BVF Inc."), which is also an investment advisor to Partners. Partners is the general partner of BVF, L.P. and BVF2, L.P. and is the manager of Investments. Pursuant to the operating agreement of Investments, Partners is authorized, among other things, to invest the funds of Ziff Asset Management, L.P., the majority member of Investments, in the shares of common stock described herein as being beneficially owned by Investments. Mark N. Lampert is the sole shareholder and sole director of BVF Inc., and is an officer of BVF Inc. This joint filing on Form 4 shall not be deemed an admission that Mark N. Lampert is, for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise, the beneficial owner of any equity securities covered by this joint filing. Mr. Lampert disclaims beneficial ownership of shares reported in this response, except to the extent that he has a pecuniary interest therein. Shares beneficially owned by BVF, L.P. Shares beneficially owned by BVF2, L.P.Shares beneficially owned by InvestmentsBVF Partners L.P., By: BVF Inc., its GP, By: /s/ Mark N. Lampert2004-01-13BIOTECHNOLOGY VALU E FUND, L.P. By: BVF Partners L.P., its GP, By: BVF Inc., By: /s/ Mark N. Lampert2004-01-13BIOTECHNOLOGY VALUE FUND II, L.P., By: BVF Partners L.P., its GP, By: BVF Inc., By: /s/ Mark N. Lampert2004-01-13BVF INVESTMENTS, L.L.C., By: BVF Partners L.P., its Manager, By: BVF Inc., By: /s/ Mark N. Lampert2004-01-13BVF INC., By: /s/ Mark N. Lampert2004-01-13 -----END PRIVACY-ENHANCED MESSAGE-----